Apsara Therapeutics develops antibody therapies for the treatment of neuromyelitis optica, a demyelinating disorder characterized by the formation of lesions on the spinal cord and the optic nerve. Its therapies block NMO lesion formation and halt the inflammatory cascade that often results in demyelination and neuronal cell death.

Apsara